新华医疗（600587）(600587.SH)发布公告，为聚焦核心主业发展，提升资产运营效率，公司全资子公 司华佗国际发展有限公司(简称"华佗国际")拟通过公开市场交易方式出售华检医疗控股有限公司(简 称"华检医疗")不超过5%的股份。 ...

智通财经APP讯，新华医疗(600587.SH)发布公告，为聚焦核心主业发展，提升资产运营效率，公司全 资子公司华佗国际发展有限公司(简称"华佗国际")拟通过公开市场交易方式出售华检医疗控股有限公司 (简称"华检医疗")不超过5%的股份。 ...

Core Viewpoint - Fosun Pharma (600196.SH) announced plans to divest 100% equity of Shanghai Clone to enhance focus on core business and improve asset operational efficiency [1] Group 1: Transaction Details - Fosun Pharma's subsidiary, Fosun Pharma Industry, plans to invest RMB 54.6 million as a limited partner (LP) to establish a special fund with Hongyi Tianjin and Zhonghui Life Insurance, expecting to hold 9.98% of the fund's assets after full fundraising [1] - Following the establishment of the special fund and fulfillment of agreed conditions, Fosun Pharma Industry intends to transfer its 100% equity in Shanghai Clone and related debts for no more than RMB 125.6 million to the special fund or its controlled entities [1] - After the transfer, the group will no longer hold equity in Shanghai Clone but will continue to lease part of the property as an operational site, with no significant impact on daily operations expected [1] Group 2: Use of Proceeds - Proceeds from the transfer will be allocated to the ongoing investment in the group's innovative drug business [1]

Core Viewpoint - Fosun Pharma plans to divest 100% equity of Shanghai Clone to focus on core business and enhance asset operation efficiency [1] Group 1: Company Actions - Fosun Pharma's subsidiary intends to transfer 100% equity of Shanghai Clone, aiming to streamline operations [1] - The company will invest 54.6 million RMB as a limited partner in a special fund alongside Hongyi Tianjin and Zhonghui Life Insurance [1] - The expected transfer value for the equity and related debts of Shanghai Clone is up to 1.256 billion RMB [1]

Core Viewpoint - Fosun Pharma (02196.HK) announced plans to divest 100% equity of Shanghai Clone to enhance focus on core business and improve asset operation efficiency [1] Group 1: Transaction Details - Fosun Pharma's subsidiary, Fosun Pharma Industry, plans to invest RMB 54.6 million as a limited partner (LP) to establish a special fund with Hongyi Tianjin and Zhonghui Life Insurance, expecting to hold 9.98% of the fund's assets after full fundraising [1] - Following the establishment of the special fund and fulfillment of agreed conditions, Fosun Pharma Industry intends to transfer its 100% equity in Shanghai Clone and related debts for no more than RMB 1.256 billion to the special fund or its controlled entities [1] - After the transfer, the group will no longer hold equity in Shanghai Clone but will continue to lease part of the property as an operating site, with no significant impact on daily operations expected [1] Group 2: Use of Proceeds - Proceeds from the transfer will be allocated to the continuous investment in the group's innovative drug business [1]

Core Viewpoint - Fosun Pharma (600196) announced on September 26 that it plans to divest 100% equity of Shanghai Clone, aiming to focus on core business and enhance asset operational efficiency [1] Group 1: Transaction Details - Fosun Pharma Industry intends to invest 54.6 million yuan as a limited partner (LP) to establish a special fund with Hongyi Tianjin and Zhonghui Life Insurance, expecting to hold 9.98% of the fund's property share [1] - Following the establishment of the special fund, Fosun Pharma Industry plans to transfer its 100% equity in Shanghai Clone and related debts to the special fund or its controlling entity for no more than 1.256 billion yuan [1]